Main Products

Chugai’s prescribed medicines are categorized into oncology and Specialty (excl. oncology).
View details in a PDF format.

Chugai Main Products PDF [PDF 318KB]

Oncology Area

Alecensa® (alectinib) ALK inhibitor
Avastin® (bevacizumab) Anti-VEGF humanized monoclonal antibody
FoundationOne® CDx Cancer Genomic Profile
FoundationOne® Liquid CDx Cancer Genomic Profile
-
Gazyva® (obinutuzumab) Anti-CD20 humanized monoclonal antibody
Herceptin® (trastuzumab) Anti-HER2 humanized monoclonal antibody
Kadcyla® (trastuzumab emtansine) Anti-HER2 antibody-tubulin polymerization inhibitor conjugate
Perjeta® (pertuzumab) Anti-HER2 humanized monoclonal antibody
Polivy® (polatuzumab vedotin) Antimicrotubule binding anti-CD79b monoclonal antibody
Tecentriq® (atezolizumab) Anti-PD-L1 humanized monoclonal antibody
Phesgo® (pertuzumab, trastuzumab and vorhyaluronidase alfa) Anti-HER2 humanized monoclonal antibody/hyaluronandegradation enzyme combination

Specialty Area (excl. Oncology)

Actemra® (tocilizumab) Humanized anti-human IL-6 receptor monoclonal antibody
CellCept® (mycophenolate mofetil) Immunosuppressant
Edirol® (eldecalcitol) Osteoporosis agent (Active vitamin D3 derivative)
Enspryng® (satralizumab) pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody
Evrysdi® (risdiplam) Spinal muscular atrophy agent
Hemlibra® (emicizumab) Anti-coagulation factor IXa/X humanized bispecific monoclonal antibody
Mircera® (epoetin beta pegol) Long-acting erythropoiesis-stimulating agent
Ronapreve® (casirivimab/imdevimab) anti-SARS-CoV-2 monoclonal antibody
Tamiflu® (oseltamivir) Anti-influenza agent
Vabysmo® (faricimab) Anti VEGF/anti Ang-2 bispecific antibody
  • Like
  • Post
  • LINE it!
  • E-mail

Main Products / Development Pipeline

Back to top